Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8841185 | 0.89 | CASP6 (0.62) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL1509549 | 0.83 | TSHR (0.60) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL10756347 | 0.82 | CASP6 (0.55) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL3582465 | 0.82 | TSHR (0.64) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL4199372 | 0.82 | VCAM1 (0.50) | TSHRTPMTLMNACYP1A2MAPT | |
| SCHEMBL3597707 | 0.81 | TSHR (0.62) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL754672 | 0.81 | TSHR (0.62) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL29795771 | 0.81 | TSHR (0.62) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL8841183 | 0.81 | CASP6 (0.53) | TSHRCASP6TPMTHCAR3LMNA | |
| SCHEMBL10607962 | 0.80 | GAA (0.51) | TSHRCASP6TPMTHCAR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| CN-100412073-C | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2008-08-20 | — | — | CN | disclosed |
| CN-101065148-A | Conjugated complement cascade inhibitors | DIMENSIONAL PHARM INC (US) | 2007-10-31 | — | — | CN | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1644046-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| CN-1665800-A | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005002627-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0206635-B1 | PREPARATION OF 3-AMINO-4-HYDROXYBENZOIC ACIDS | THE DOW CHEMICAL COMPANY (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0206635-A1 | Preparation of 3-amino-4-hydroxybenzoic acids | THE DOW CHEMICAL COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TSHR 110/4885CASP6 1688/4885TPMT 104/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TSHR 247/4885CASP6 1649/4885TPMT 62/4885 |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | C9, CFH, CFB | TSHR 2818/4885CASP6 1108/4885TPMT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.